This is Psychedellux, the week’s top news in the psychedelic industry
Psychedelic medicine company Compass Pathways plc (Nasdaq: CMPS) reported its financial results for the fourth quarter and year-end 2020 and gave an update on recent progress across its business. Compass delivered a net loss for the quarter ending in December 2020 was $18.8 million, or $0.52 loss per share versus last year’s net loss of $7.6 million, or $0.90 loss per share for the same period in 2019. The earnings beat the average analyst estimate according to Yahoo Finance which was for a loss of $1.05. The stock was trading slightly higher and was lately selling at $39.
Psychedelic medicine biotech company Mind Medicine (MindMed) Inc. (OTCQB: MMEDF) has entered into a bought deal private placement that raised roughly $15.4 million
NeonMind is exploring psilocybin as an innovative treatment approach to support weight loss. The company said it has engaged Certara, a leader in model-informed drug development to provide strategic drug development support for the investigation
Cybin Inc. (OTCQB:CLXPF) announced that its shares began trading on the OTCQB Venture Market on March 8, 2021, under the symbol “CLXPF.”